Stocks Health care STXS
NYSE · Health careStereotaxis, Inc. (STXS)
Stereotaxis, Inc. brought in $30.1M of revenue over the twelve months to June 30, 2026, down 5.5% from a year earlier. It posted a net loss of $22.3M. In fiscal 2025 capital spending exceeded operating cash flow by $13.8M. At June 30, 2026 it held $10.5M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 12, 2026.
Key facts about Stereotaxis, Inc.
- Net worth
- Stereotaxis, Inc. has a market value (market cap) of $103.2M at the latest share price, and shareholders' equity of $12.2M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $32.4M (+20.3% year on year), with a net loss of $21.6M. Over the 12 months to June 30, 2026: revenue $30.1M, net loss $22.3M.
- Cash flow
- In fiscal 2025 operations used $13.7M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 12, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Stereotaxis, Inc.'s next report is expected around November 11, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
What Stereotaxis, Inc. does
Stereotaxis, Inc. is registered with the SEC under industry code SIC 3845 (Electromedical & Electrotherapeutic Apparatus). Its shares trade on NYSE under the ticker STXS.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $32.4M | -$21.6M | -$0.25 | -$13.8M |
| 2024 | $26.9M | -$24M | -$0.30 | -$8.5M |
| 2023 | $26.8M | -$20.7M | -$0.27 | -$9.5M |
| 2022 | $28.1M | -$18.3M | -$0.26 | -$10.8M |
| 2021 | $35M | -$10.7M | -$0.16 | -$4.3M |
| 2020 | $26.6M | -$6.6M | -$0.11 | -$3.6M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where STXS ranks in Health care
Latest SEC filings
What Stereotaxis, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 19, 2026Passive stake (5% or more) SCHEDULE 13G
- August 12, 2026Quarterly report 10-Q · period to June 30, 2026Revenue fell 13% to $7.7M versus the same quarter last year; diluted EPS -$0.05 versus -$0.05.
- August 11, 2026
- July 16, 2026Other event 8-K
- July 15, 2026
- July 15, 2026
- July 9, 2026
- May 29, 2026
- May 15, 2026Passive stake changed SCHEDULE 13G/A
- May 15, 2026
Insider trades
What the people running Stereotaxis, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| July 1, 2026 | Menawat Arun SwarupDirector | Received as pay | 43,103 | - |
| July 1, 2026 | Curet MyriamDirector | Received as pay | 43,103 | - |
| July 1, 2026 | Fischel NathanDirector, 10% owner | Received as pay | 43,103 | - |
| July 1, 2026 | Levin Ross BDirector | Received as pay | 43,103 | - |
| July 1, 2026 | Benfer DavidDirector | Received as pay | 43,103 | - |
| July 1, 2026 | Shamir NachumDirector | Received as pay | 43,103 | - |
| January 2, 2026 | Shamir NachumDirector | Received as pay | 46,948 | - |
| January 2, 2026 | Levin Ross BDirector | Received as pay | 46,948 | - |
Who owns STXS
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Daniel Louis Kaufman13G, passive | 5.9% | August 19, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 109 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| DAFNA Capital Management LLC | 13,680,554 | 0 |
| BlackRock, Inc. | 4,396,835 | +440,592 |
| Lagoda Investment Management, L.P. | 4,122,600 | -227,800 |
| Vanguard Capital Management LLC | 3,044,820 | +46,776 |
| Arbiter Partners Capital Management LLC | 2,883,856 | 0 |
| Geode Capital Management, LLC | 1,895,243 | +219,835 |
| Essex Investment Management Co LLC | 1,521,966 | -68,135 |
| Archon Capital Management LLC | 1,226,044 | 0 |
| Warberg Asset Management LLC | 1,108,889 | +14,766 |
| State Street Corp | 916,780 | -40,988 |
| AlphaCentric Advisors LLC | 600,000 | 0 |
| Vanguard Fiduciary Trust Co | 589,110 | +59,240 |
| Bank Julius Baer & Co. Ltd, Zurich | 540,530 | +1 |
| Northern Trust Corp | 529,695 | +32,769 |
| Legato Capital Management LLC | 512,907 | +15,384 |
| Vanguard Portfolio Management LLC | 463,580 | +94,951 |
| Sequoia Financial Advisors, LLC | 381,355 | +703 |
| Morgan Stanley | 332,107 | +201,304 |
| UBS Group AG | 251,333 | +14,055 |
| Prescott Group Capital Management, L.L.C. | 237,495 | 0 |
Insiders
7 insiders reported holding 6,434,902 shares in total, about $6.6M at the last price.
| Holder | Shares |
|---|---|
| Isaac Paul JDirector | 2,883,8562,786,557 held indirectly |
| Menawat Arun SwarupDirector | 1,035,560 |
| Fischel NathanDirector, 10% owner | 720,775 |
| Levin Ross BDirector | 621,248 |
| Benfer DavidDirector | 558,975 |
| Curet MyriamDirector | 435,161 |
| Shamir NachumDirector | 179,327 |
Questions about STXS
What does Stereotaxis, Inc. do?
Stereotaxis, Inc. is a company in the Health care sector, listed on NYSE as STXS. Its shares trade on NYSE under the ticker STXS.
What is Stereotaxis, Inc.'s net worth?
Stereotaxis, Inc. has a market value (market cap) of $103.2M at the latest share price, and shareholders' equity of $12.2M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Stereotaxis, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $22.3M on revenue of $30.1M.
How much revenue does Stereotaxis, Inc. make?
Over the twelve months to June 30, 2026 Stereotaxis, Inc. reported revenue of $30.1M. That is 5.5% less than a year earlier.
When did Stereotaxis, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 12, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the passive stake (5% or more) from August 19, 2026.
When is Stereotaxis, Inc.'s next earnings report?
Stereotaxis, Inc.'s next report is expected around November 11, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare STXS with
Follow STXS
Get an email when Stereotaxis, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Stereotaxis, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.